The lab: Gargiulo group
Our group is composed of currently nine fellows and is gender and nationality wise balanced. We host and train researchers with both wet and dry lab expertise and we had MDs sitting inour lab meeting frequently. Provided that the trainee had a solid clinical or biomedical training, our lab is a valuable asset for the trainee and we do benefit from fellows with a patient-oriented mindset. We currently interact with several clinicians at Charité or elsewhere. In particular, we haveexisting collaborations with Prof. David Capper and Dr. Katja von Hoff with whom we share interest in rare pediatric brain tumors, with Prof. Michael Synowitz and Dr. Charlotte Fluh, with whom we liaise for high-grade brain tumors, and with Dr. Anton Henssen, with whom collaborations are in place to study neuroblastoma.
The position
What’s the main purpose of our research?
We investigate the molecular mechanisms regulating tumor homeostasis and response to anti-cancer therapy.
How we will do it?
We focus on adult and pediatric brain tumors, and on non-small cell lung cancer.
Why is this important?
Glioblastoma is heterogeneous and incurable. For years, many seminal studies have shown that glioblastoma exists as a heterogeneous mix of multiple entities or cell states but discriminating between entities and states is difficult. Moreover, several clinically relevant covariates, such as differentiation, inflammation, radiotherapy, hypoxia, and infiltration by innate immune cells were shown to correlate with a glioblastoma state transition.
Other positions
IDIBAPS#4 – Mechanisms involved in strenuous exercise-induced atrial myocardial fibrosis
IC#4 – The role polyglutamylation in tauopathic neurodegeneration
IC#3 – Evaluation of the efficiency of immunotherapy by tracing ctDNA in metastatic NSCLC and triple-negative breast cancer patients
IC#2 – New targetable vulnerabilities for the treatment of chemoresistant breast and ovarian BRCA1/2-mutated tumors
IDIBAPS#3 – Mechanisms involved in vascular inflammation/remodeling in systemic vasculitis
IDIBAPS#2 – Mechanisms and therapies for Myeloma, amyloidosis, macroglobulinemia and other gammapathies
IDIBAPS#1 – Developing and investigating computing, machine learning and physiological modelling for understanding each individual heart towards personalised medicine
BRIC#6 – Tumour evolution, heterogeneity, and understanding of the mutational processes leading to aggressive disease
IC#1 – The role of RNASE1 in lung metastatic niche establishment by breast cancer cells
MDC#3 – Neuromuscular and Cardiovascular Cell Biology
MDC#2 – Molecular and cellular basis of behavior
MDC#1 – Host-microbiome factors in cardiovascular disease
NKI#1 – Epigenetic regulation in hormone-driven cancers and therapy resistance
VIB#8 – Mechanisms of inflammation and associated tissue damage in musculoskeletal diseases
VIB#7 – Endothelial immunosuppressive mystery genes for alternative immunotherapy: artificial intelligence-driven target discovery and validation
VIB#6 – Cellular metabolism and metabolic regulation in cancer metastasis
VIB#5 – Unraveling the molecular mechanisms of neuronal degeneration in motor neuron diseases
VIB#4 – Identification of universal biomarkers of metastatic melanoma in CTCs
VIB#3 – Basic mechanisms of Alzheimer’s disease and neurodegeneration
VIB#2 – Integrative genomics to underpinning somatic evolution, tumour heterogeneity, and treatment resistance
VIB#1 – Medical biotechnology to improve hepatocellular carcinoma diagnostics
BRIC#5 – The impact of severe maternal respiratory tract infections on fetal brain development and offspring behavior
